P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

• Jennifer Woyach,
• Ian W. Flinn,
• Farrukh Awan,
• Herbert Eradat,
• Danielle M. Brander,
• Michael Tees,
• Sameer Parikh,
• Tycel Phillips,
• Razi Ghori,
• Ima Paydar,
• Mohammed Z. H. Farooqui,
• John C. Byrd,
• Deborah Stephens

Affiliations

Jennifer Woyach

1 The Ohio State University, Columbus, United States

Ian W. Flinn

2 Sarah Cannon Research Institute, Nashville, United States

Farrukh Awan

3 University of Texas Southwestern Medical Center, Dallas, United States

Herbert Eradat

4 David Geffen School of Medicine at UCLA, Los Angeles, United States

Danielle M. Brander

5 Duke University, Duke PDC, Durham, United States

Michael Tees

6 Colorado Blood Cancer Institute, Denver, United States

Sameer Parikh

7 Mayo Clinic, Rochester, United States

Tycel Phillips

8 University of Michigan Rogel Cancer Center, Ann Arbor, United States

Razi Ghori

9 Merck & Co., Inc., Rahway, United States

Ima Paydar

9 Merck & Co., Inc., Rahway, United States

Mohammed Z. H. Farooqui

9 Merck & Co., Inc., Rahway, United States

John C. Byrd

10 University of Cincinnati College of Medicine, Cincinnati, United States

Deborah Stephens

11 University of Utah Huntsman Cancer Institute, Salt Lake City, United States